Full Text:   <1383>

CLC number: R734.2

On-line Access: 2011-03-09

Received: 2010-06-01

Revision Accepted: 2010-10-18

Crosschecked: 2011-02-15

Cited: 9

Clicked: 3776

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2011 Vol.12 No.3 P.174-179

10.1631/jzus.B1000197


RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum


Author(s):  Lin-run Wang, Guo-bing Zhang, Jian Chen, Jun Li, Ming-wei Li, Nong Xu, Yang Wang, Jian-zhong Shentu

Affiliation(s):  Department of Pharmacy, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China, Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China, Clinical Laboratory, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China

Corresponding email(s):   myathena100@yahoo.com.cn, stjz@zju.edu.cn

Key Words:  Gemcitabine, Ribonucleotide reductase M1 (RRM1), Breast cancer susceptibility gene 1 (BRCA1), Non-small-cell lung cancer (NSCLC), Gene expression


Lin-run Wang, Guo-bing Zhang, Jian Chen, Jun Li, Ming-wei Li, Nong Xu, Yang Wang, Jian-zhong Shentu. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum[J]. Journal of Zhejiang University Science B, 2011, 12(3): 174-179.

@article{title="RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum",
author="Lin-run Wang, Guo-bing Zhang, Jian Chen, Jun Li, Ming-wei Li, Nong Xu, Yang Wang, Jian-zhong Shentu",
journal="Journal of Zhejiang University Science B",
volume="12",
number="3",
pages="174-179",
year="2011",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1000197"
}

%0 Journal Article
%T RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum
%A Lin-run Wang
%A Guo-bing Zhang
%A Jian Chen
%A Jun Li
%A Ming-wei Li
%A Nong Xu
%A Yang Wang
%A Jian-zhong Shentu
%J Journal of Zhejiang University SCIENCE B
%V 12
%N 3
%P 174-179
%@ 1673-1581
%D 2011
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1000197

TY - JOUR
T1 - RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum
A1 - Lin-run Wang
A1 - Guo-bing Zhang
A1 - Jian Chen
A1 - Jun Li
A1 - Ming-wei Li
A1 - Nong Xu
A1 - Yang Wang
A1 - Jian-zhong Shentu
J0 - Journal of Zhejiang University Science B
VL - 12
IS - 3
SP - 174
EP - 179
%@ 1673-1581
Y1 - 2011
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1000197


Abstract: 
Objective: To evaluate the predictive values of gene expressions of ribonucleotide reductase M1 (RRM1) and breast cancer susceptibility gene 1 (BRCA1) in peripheral blood from Chinese patients with non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum. Methods: Forty Chinese patients with advanced NSCLC were recruited and received gemcitabine 1 200 mg/m2 on Days 1 and 8 plus carboplatin AUC 5 on Day 1. RRM1 and BRCA1 expression levels in peripheral blood were detected by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Kaplan-Meier survival curve and log-rank test were performed to evaluate the correlation between gene expression and overall survival for these subjects. Results: No correlation was observed between gene expression of RRM1 and that of BRCA1 (P>0.05), but there was a strong correlation between the expression of RRM1 and the response to chemotherapy (P=0.003). Subjects with low RRM1 expression levels in peripheral blood had longer survival time than those with high RRM1 expression levels (16.95 vs. 12.76 months, log-rank 3.989, P=0.046). However, no significant association between BRCA1 expression levels and survival time was found (16.80 vs. 13.77 months, log-rank 0.830, P=0.362). Conclusions: Patients with low RRM1 expression levels in peripheral blood have a greater response to chemotherapy and longer survival time. Advanced NSCLC patients with low RRM1 expression levels may benefit from gemcitabine plus platinum therapy. RRM1 mRNA expression in peripheral blood could be used to predict the prognosis of NSCLC treated by gemcitabine and platinum.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K.D., Danenberg, P.V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al., 2006. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol., 17(12):1818-1825.

[2]Davidson, J.D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L.M., Slapak, C.A., 2004. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res., 64(11):3761-3766.

[3]Dong, S., Guo, A.L., Chen, Z.H., Wang, Z., Zhang, X.C., Huang, Y., Xie, Z., Yan, H.H., Cheng, H., Wu, Y.L., 2010. RRM1 single nucleotide polymorphism −37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J. Hematol. Oncol., 3(1):10.

[4]Gautam, A., Li, Z.R., Bepler, G., 2003. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene, 22(14):2135-2142.

[5]Goan, Y.G., Zhou, B., Hu, E., Mi, S., Yen, Y., 1999. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res., 59(17):4204-4207.

[6]Isla, D., Sarries, C., Rosell, R., Alonso, G., Domine, M., Taron, M., Lopez-Vivanco, G., Camps, C., Botia, M., Nunez, L., et al., 2004. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol., 15(8):1194-1203.

[7]Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Thun, M.J., 2007. Cancer statistics, 2007. CA Cancer J. Clin., 57(1):43-66.

[8]Quinn, J.E., Kennedy, R.D., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G., Harkin, D.P., 2003. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res., 63(19):6221-6228.

[9]Quinn, J.E., James, C.R., Stewart, G.E., Mulligan, J.M., White, P., Chang, G.K., Mullan, P.B., Johnston, P.G., Wilson, R.H., Harkin, D.P., 2007. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res., 13(24):7413-7420.

[10]Rosell, R., Scagliotti, G., Danenberg, K.D., Lord, R.V., Bepler, G., Novello, S., Cooc, J., Crino, L., Sanchez, J.J., Taron, M., et al., 2003. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 22(23):3548-3553.

[11]Rosell, R., Danenberg, K.D., Alberola, V., Bepler, G., Sanchez, J.J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., et al., 2004a. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res., 10(4):1318-1325.

[12]Rosell, R., Felip, E., Taron, M., Majo, J., Mendez, P., Sanchez-Ronco, M., Queralt, C., Sanchez, J.J., Maestre, J., 2004b. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res., 10(12 Pt 2):4215s-4219s.

[13]Rosell, R., Skrzypski, M., Jassem, E., Taron, M., Bartolucci, R., Sanchez, J.J., Mendez, P., Chaib, I., Perez-Roca, L., Szymanowska, A., et al., 2007. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One, 2(11):e1129.

[14]Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M.S., Queralt, C., Majo, J., Sanchez, J.M., Sanchez, J.J., et al., 2004. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet., 13(20):2443-2449.

[15]Wang, L.R., Wu, X.H., Huang, M.Z., Cai, J., Xu, N., Liu, J., 2007a. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 60(2):211-218.

[16]Wang, L.R., Huang, M.Z., Zhang, G.B., Xu, N., Wu, X.H., 2007b. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 60(4):601-607.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE